FDA Approves First Nasal Spray for Treatment-Resistant Depression
On Tuesday, January 21st, the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal spray, Spravato, as the first standalone treatment for individuals with treatment-resistant depression. This innovative ...
